NASDAQ
Hikma Pharmaceuticals PLC (HKMPY) has a price/fcf ratio of 28.48x as of Tuesday, May 26, 2026. This represents a 90.23% increase compared to its 12-month average of 14.97x. The price-to-free-cash-flow ratio measures a stock's price relative to its free cash flow per share, reflecting how efficiently a company generates cash.
No price data available for this timeframe.